MedTrace Logo

Safety for 24 Weeks Intake of Korean Red Ginseng in Adults

NCT02428998 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2017-08-11

No results posted yet for this study

Summary

Korean Red Ginseng appears to adverse events in adults taking 24 weeks Placebo and comparative assessment. And exploratory as Korean Red Ginseng blood sugar control, reduce body fat, URTI prevention, cardiovascular risk, renal function, cholesterol, improve, fatigue, and determine the impact on biological age.

Conditions

Interventions

DIETARY_SUPPLEMENT

Korean Red Ginseng

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Korea Ginseng Corporation

    lead INDUSTRY

Principal Investigators

  • Kyungsoo Kim, M.D., Ph.D · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-08-31
Completion
2017-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428998 on ClinicalTrials.gov